

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis of L-Sangivamycin and Toyocamycin Analogues and Their Inhibitory Activities of SER/THR Protein Kinases

Moon Woo Chun^a; Dae Hong Shin^a; Sun Yong Song^a; Yong Hee Lee^a; Chul Hoon Lee^b; Lak Shin Jeong^c; Seung Ki Lee^a

^a College of Pharmacy, Seoul National University, Seoul ^b Research and Development Center, Cheil Foods & Chemicals Inc., Ichun, Korea ^c Laboratory of Medicinal Chemistry, College of Pharmacy, Ewha Womans University, Seoul, Korea

To cite this Article Chun, Moon Woo , Shin, Dae Hong , Song, Sun Yong , Lee, Yong Hee , Lee, Chul Hoon , Jeong, Lak Shin and Lee, Seung Ki(1999) 'Synthesis of L-Sangivamycin and Toyocamycin Analogues and Their Inhibitory Activities of SER/THR Protein Kinases', *Nucleosides, Nucleotides and Nucleic Acids*, 18: 4, 617 – 618

To link to this Article: DOI: 10.1080/15257779908041516

URL: <http://dx.doi.org/10.1080/15257779908041516>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**SYNTHESIS OF L-SANGIVAMYCIN AND TOYOCAMYCIN
ANALOGUES AND THEIR INHIBITORY ACTIVITIES OF SER/THR
PROTEIN KINASES**

Moon Woo Chun,* Dae Hong Shin, Sun Yong Song, Yong Hee Lee, Chul Hoon Lee,¹
Lak Shin Jeong² and Seung Ki Lee*


College of Pharmacy, Seoul National University, Seoul 151-742, ¹Research and
Development Center, Cheil Foods & Chemicals Inc., Ichun 467-810, Korea and
²Laboratory of Medicinal Chemistry, College of Pharmacy, Ewha Womans University,
Seoul 120-750, Korea

Abstract: Novel L-sangivamycin and toyocamycin analogues were synthesized and evaluated for Cdc2 protein kinase activity. Among the compounds tested, L-xylose derivative and L-arabinose derivative exhibited potent inhibitory activity against Cdc2 protein kinase with IC₅₀ values of 3.7 and 1.6 μ M, respectively.

Ser/Thr protein kinases play important roles in signal transduction pathways that control the proliferation and differentiation of eukaryotic cells.¹ It was reported that sangivamycin and toyokamycin isolated from soil microorganisms exhibited potent inhibitory activity against Cdc2 protein kinase, a cyclin-dependent and Ser/Thr protein kinase.² In an attempt to search for a specific inhibitor that inhibits the Cdc2 protein kinase with a minimum side effect on other Ser/Thr protein kinase activity, we synthesized L-derivatives of these second microbial metabolites and evaluated them for Cdc2 protein kinase inhibitory activity.

Synthesis of the target nucleosides **1-4** is shown in Scheme 1. L-Arabinofuranosyl acetate was first condensed with silylated pyrrolo[2,3-d]pyrimidine bases in the presence of TMSOTf as a Lewis acid to give the only α nucleosides which were deprotected with sodium methoxide to afford the final α nucleoside analogues **1** and **2**, respectively. For the synthesis of L-xylose derivatives, L-xylofuranosyl acetate was condensed with silylated pyrrolo[2,3-d]pyrimidine bases to afford the only β nucleosides which were deprotected with sodium methoxide to afford the final β nucleoside analogues **3** and **4**, respectively.³

Scheme 1



Among the synthesized compounds tested, it was found that compound **4** exhibited the potent Cdc2 protein kinase inhibitory activity with IC₅₀ value of 1.6 μ M, while compound **2** showed weaker activity (IC₅₀ = 3.7 μ M) than compound **4**. The inhibitory activities were similar to those of other reported Cdc2 kinase inhibitors such as olomoucine (IC₅₀ = 7.0 μ M) and butyrolactone-1 (IC₅₀ = 0.6 μ M). Compounds **2** and **4** also inhibited other Ser/Thr protein kinase activity such as cAMP-dependent protein kinase (PKA),⁴ casein kinase II (CK II) and protein kinase C (PKC), but only with at two to three order magnitude higher concentrations than those inhibiting Cdc2 kinase activity (IC₅₀ = 290 μ M for PKA and IC₅₀ = 70 μ M for CK II). It is presumed that this selective activity may result from binding poorly to the ATP binding sites of other protein kinases since the synthesized L-derivatives **2** and **4** do not exist in nature. Other compounds **1** and **3** were found to show no inhibitory activity.

Acknowledgment

This research was supported by the grant from the Good Health R&D project, Ministry of Health and Welfare, Korea.

References

1. Hunter, T.; Pines, J. *Cell* **1994**, *79*, 573-582.
2. Park, S. G.; Cheon, J. Y.; Lee, Y. H.; Park, J.-S.; Lee, K. Y.; Lee, C. H.; Lee, S. K. *Mol. Cells* **1996**, *6*, 679-683.
3. Renau, T. E.; Watring, L. I.; Drach, J. G.; Townsend, L. B. *J. Med. Chem.* **1996**, *39*, 873-880.
4. Meijer, L. *Trends Cell Biol.* **1996**, *6*, 393-397.